Curriculum
Clinical training
During the Transplant Hepatology Fellowship, you acquire skills in patient diagnosis and management, procedural techniques, teaching, and research.
Rotation schedule
This is a typical rotation schedule:
Rotation | Length |
---|---|
Liver transplant (outpatient) | 2-3 months |
Liver transplant service (inpatient) | 4-5 months |
Hepatobiliary clinic (outpatient) | 2-3 months |
Hepatology research | 2-3 months |
Elective rotations may be considered after discussion with the program director in areas such as interventional radiology, advanced endoscopy, liver pathology, hepatobiliary neoplasia, cholestasis subspecialty clinic, and hepatobiliary consults.
Didactic training
Clinical conferences, seminars, small discussion groups, journal clubs and one-on-one instruction are all integral parts of the fellowship.
Research training
Innovative clinical and basic science research have enabled Mayo Clinic to remain at the forefront of liver transplantation. For example, the allocation system for liver transplantation — Model for End-Stage Liver Disease (MELD) score — was first proposed, designed, and tested by physicians at Mayo Clinic's campus in Rochester, Minnesota.
Over the last decade, hundreds of publications and talks have been presented by Mayo Clinic staff and fellows at national and international meetings. Mayo Clinic is renowned for its leadership role in the transplantation of patients with a variety of liver disorders and diseases.
Each fellow has an opportunity to conduct research under the supervision of a mentor within a broad spectrum of projects in clinical investigation and basic science research. A formal mentorship committee will assist fellows in reaching their academic goals.
Recent graduate publications
- Triple-Phase Computed Tomography May Replace Dual-Energy X-ray Absorptiometry Scan for Evaluation of Osteoporosis in Liver Transplant Candidates. Izzy M, Addissie BD, Arab JP, Hilscher MB, Cartee A, Lee DC, Lee Y, Fletcher JG, Keaveny TM, Sanchez W.Liver Transpl. 2021 Feb;27(3):341-348. doi: 10.1002/lt.25926. Epub 2021 Mar 4.PMID: 33098253
- Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease. Yang JD, Ahmed F, Mara KC, Addissie BD, Allen AM, Gores GJ, Roberts LR.Hepatology. 2020 Mar;71(3):907-916. doi: 10.1002/hep.30858. Epub 2019 Oct 21.PMID: 31309602
- GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. Yang JD, Addissie BD, Mara KC, Harmsen WS, Dai J, Zhang N, Wongjarupong N, Ali HM, Ali HA, Hassan FA, Lavu S, Cvinar JL, Giama NH, Moser CD, Miyabe K, Allotey LK, Algeciras-Schimnich A, Theobald JP, Ward MM, Nguyen MH, Befeler AS, Reddy KR, Schwartz M, Harnois DM, Yamada H, Srivastava S, Rinaudo JA, Gores GJ, Feng Z, Marrero JA, Roberts LR.Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):531-538. doi: 10.1158/1055-9965.EPI-18-0281. Epub 2018 Nov 21.PMID: 30464023
- Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Yang JD, Mohamed EA, Aziz AO, Shousha HI, Hashem MB, Nabeel MM, Abdelmaksoud AH, Elbaz TM, Afihene MY, Duduyemi BM, Ayawin JP, Gyedu A, Lohouès-Kouacou MJ, Ndam AW, Moustafa EF, Hassany SM, Moussa AM, Ugiagbe RA, Omuemu CE, Anthony R, Palmer D, Nyanga AF, Malu AO, Obekpa S, Abdo AE, Siddig AI, Mudawi HM, Okonkwo U, Kooffreh-Ada M, Awuku YA, Nartey YA, Abbew ET, Awuku NA, Otegbayo JA, Akande KO, Desalegn HM, Omonisi AE, Ajayi AO, Okeke EN, Duguru MJ, Davwar PM, Okorie MC, Mustapha S, Debes JD, Ocama P, Lesi OA, Odeghe E, Bello R, Onyekwere C, Ekere F, Igetei R, Mah'moud MA, Addissie B, Ali HM, Gores GJ, Topazian MD, Roberts LR; Africa Network for Gastrointestinal and Liver Diseases.Lancet Gastroenterol Hepatol. 2017 Feb;2(2):103-111. doi: 10.1016/S2468-1253(16)30161-3. Epub 2016 Dec 3.PMID: 28403980
- Cirrhotic Cardiomyopathy Predicts Post-Transplant Cardiovascular Disease: Revelations of The New Diagnostic Criteria. Izzy M, Soldatova A, Sun X, Angirekula M, Mara K, Lin G, Watt K.Liver Transpl. 2021 Feb 3. doi: 10.1002/lt.26000. Online ahead of print.PMID: 33533556
- Triple-Phase Computed Tomography May Replace Dual-Energy X-ray Absorptiometry Scan for Evaluation of Osteoporosis in Liver Transplant Candidates. Izzy M, Addissie BD, Arab JP, Hilscher MB, Cartee A, Lee DC, Lee Y, Fletcher JG, Keaveny TM, Sanchez W.Liver Transpl. 2021 Feb;27(3):341-348. doi: 10.1002/lt.25926. Epub 2021 Mar 4.PMID: 33098253
- Role of symmetric dimethylarginine in predicting future renal impairment in liver transplant recipients. Izzy M, Angirekula M, Bentall A, Plevak M, Dierkhising R, Lerman LO, Tang H, Hickson L, Watt KD.Transpl Int. 2020 Oct 17. doi: 10.1111/tri.13771. Online ahead of print.PMID: 33070373
- The Transcriptome of Hepatic Fibrosis Revealed by Single-Cell RNA Sequencing. Jophlin LL, Cao S, Shah VH.Hepatology. 2020 May;71(5):1865-1867. doi: 10.1002/hep.31155.PMID: 32017148
- Hepatic stellate cells retain retinoid-laden lipid droplets after cellular transdifferentiation into activated myofibroblasts. Jophlin LL, Koutalos Y, Chen C, Shah V, Rockey DC.Am J Physiol Gastrointest Liver Physiol. 2018 Nov 1;315(5):G713-G721. doi: 10.1152/ajpgi.00251.2017. Epub 2018 Jul 19.PMID: 30024770
- Transarterial radioembolization versus systemic treatment for hepatocellular carcinoma with macrovascular invasion: Analysis of the US National Cancer Database. Ahn JC, Lauzon M, Luu M, Friedman ML, Kosari K, Nissen N, Lu SC, Roberts LR, Singal AG, Yang JD.J Nucl Med. 2021 Apr 9:jnumed.121.261954. doi: 10.2967/jnumed.121.261954. Online ahead of print.PMID: 33837067
- Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease. Yang JD, Ahmed F, Mara KC, Addissie BD, Allen AM, Gores GJ, Roberts LR.Hepatology. 2020 Mar;71(3):907-916. doi: 10.1002/hep.30858. Epub 2019 Oct 21.PMID: 31309602
- External validation of the United Kingdom-primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid. Cheung AC, Gulamhusein AF, Juran BD, Schlicht EM, McCauley BM, de Andrade M, Atkinson EJ, Lazaridis KN.Hepatol Commun. 2018 Apr 24;2(6):676-682. doi: 10.1002/hep4.1186. eCollection 2018 Jun.PMID: 29881819
- Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Hepatology Highlights. Mousa OY, Malhi H, Russo N, Jesudian A, Pisa JF, Kulai TB, Maiers JL, Kostallari E, Jalan-Sakrikar N, Tafesh ZH, Fortune BE, Yang L, Lau DTY, Nair K, Wedd J.Hepatology. 2019 Jul;70(1):1-4. doi: 10.1002/hep.30808.PMID: 31245883
- Bile Acid Profiles in Primary Sclerosing Cholangitis and their Ability to Predict Hepatic Decompensation. Mousa OY, Juran BD, McCauley BM, Vesterhus MN, Folseraas T, Turgeon CT, Ali AH, Schlicht EM, Atkinson EJ, Hu C, Harnois D, Carey EJ, Gossard AA, Oglesbee D, Eaton JE, LaRusso NF, Gores GJ, Karlsen TH, Lazaridis KN.Hepatology. 2020 Nov 23. doi: 10.1002/hep.31652. Online ahead of print.PMID: 33226645
- Injury pattern recognition to discriminate competing causes of liver injury. Talaat N, Tillmann HL.Liver Int. 2019 May;39(5):821-825. doi: 10.1111/liv.14056. Epub 2019 Feb 13.PMID: 30703293
- Small but Mighty: Platelets in NASH and Other Chronic Liver Diseases. Hilscher MB, Shah VH.Hepatology. 2020 Apr;71(4):1501-1504. doi: 10.1002/hep.31101. Epub 2020 Mar 18.PMID: 31903616
- Mechanical Stretch Increases Expression of CXCL1 in Liver Sinusoidal Endothelial Cells to Recruit Neutrophils, Generate Sinusoidal Microthombi, and Promote Portal Hypertension. Hilscher MB, Sehrawat T, Arab JP, Zeng Z, Gao J, Liu M, Kostallari E, Gao Y, Simonetto DA, Yaqoob U, Cao S, Revzin A, Beyder A, Wang RA, Kamath PS, Kubes P, Shah VH.Gastroenterology. 2019 Jul;157(1):193-209.e9. doi: 10.1053/j.gastro.2019.03.013. Epub 2019 Mar 11.PMID: 30872106
Moonlighting
This one year fellowship is dedicated to focused training and research in hepatobiliary disease and liver transplantation. Therefore, any moonlighting activities require discussion with and approval from the program director.
Evaluation
To ensure that you gain proficiency and develop the corresponding technical skills, your performance is monitored throughout the Transplant Hepatology Fellowship. You are formally evaluated by your supervising faculty member after completing each clinical rotation, and you will meet with the program director quarterly to review these evaluations. In addition, you will regularly have the opportunity to evaluate the faculty to ensure that your educational goals are being met.